Prevention and Treatment of Multidrug-Resistant Organisms in End-Stage Renal Disease

Publication date: January 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 1Author(s): John K. Midturi, Sangeetha RanganathChronic kidney disease patients are at high risk for infections because of multidrug-resistant organisms. Infections are the second most common cause of death in patients with ESRD. Patients with ESRD are prone to infections given alterations in immunity, increased rates of colonization with multidrug-resistant organisms, increased hospitalizations, and interactions with health care systems. Infections range from urinary tract infections, pneumonia, skin and soft tissue infections, central line–associated bloodstream infections to sepsis. A coordinated collaborative effort using a multipronged approach must be stressed to reduce the burden of infections. Preventive measures such as hand hygiene, antibiotic stewardship, immunizations, and minimizing central venous catheters are critical to curtail infections with multidrug-resistant organisms. Empirical and targeted treatment for multidrug-resistant organisms may require collaboration with infectious disease providers to improve outcomes in these serious infections. It is imperative to address multidrug-resistant organisms in ESRD patients at this juncture to improve medical outcomes now and for the future.
Source: Advances in Chronic Kidney Disease - Category: Urology & Nephrology Source Type: research